Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort

Pop‐Busui, Rodica; Lu, Jiang; Lopes, Neuza; Jones, Teresa L.Z.

doi:10.1111/j.1529-8027.2009.00200.x

Cited by 111 publications

(89 citation statements)

References 30 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A population-based study has indicated that neuropathy develops in as many as 50% of all patients with type 1 or type 2 diabetes 187 . Neuropathic pain develops in >30% of these patients, meaning that approximately one in six patients with diabetes develops a painful neuropathy [188][189][190] .…”

Section: Schwann Cells In Diabetic Neuropathymentioning

confidence: 99%

Schwann cell interactions with axons and microvessels in diabetic neuropathy

et al. 2017

View full text Add to dashboard Cite

The incidence of diabetes mellitus has increased dramatically over the past two to three decades. According to the International Diabetes Federation Diabetes Atlas, 415 million people worldwide had diabetes in 2015, and this number is expected to grow by 5% annually, predominantly as a result of increasing prevalence of type 2 diabetes. Furthermore, an estimated 100 million Europeans and 80 million Americans have impaired glucose tolerance or prediabetes. Few people die from acute diabetes in countries with comprehensive health care systems, but the disease is inflicting a huge medical, social and economic burden on society owing to the need for lifelong treatment of its systemic consequences and the insidious development of multi-organ damage.Peripheral neuropathy (BOXES 1,2) is a common but often neglected complication of long-term diabetes, and the lack of treatment options reflects an incomplete understanding of the pathogenic mechanisms. Hyperglycaemia is generally accepted as the primary pathogenic insult in type 1 and type 2 diabetic neuropathy, although roles are emerging for other factors, such as impaired insulin signalling, hypertension and dyslipidaemia (particularly for type 2 diabetes), which might precede overt hyperglycaemia 1 . Many preclinical studies, and occasional clinical studies, have indicated that diabetic neuropathy -like diabetic nephropathy and retinopathy -results from microvascular disease, with a focus on axonal degeneration as a consequence of ischaemia and/or hypoxia. This mechanism, however, is likely to be only one aspect of a more complex pathogenesis.The earliest descriptions of pathology in diabetic neuropathy indicated that Schwannopathy accompanied axonal degeneration. The majority of clinical and basic research in diabetic neuropathy since then has focused on the effects on neurons. However, accumulating data from research into the development and regeneration of the PNS has identified Schwann cells as equally indispensable components that maintain neuronal structure and function, nourish axons, and promote survival and growth upon injury. The early reports from 1979 that demonstrated morphological changes in Schwann cells in human diabetic neuropathy 2 are now supported by an increased awareness of molecular alterations in Schwann cells during diabetes 3 . Schwann cells express a wide range of receptors and, when they sense insults or danger signals, they upregulate synthesis and secretion of factors that stimulate neuroprotection, regrowth and remyelination, or factors that aggravate disease phenotypes 4 . The most recent studies have demonstrated that Schwann cells regulate many aspects of axonal function, so that disruption of their metabolism by diabetes results in the accumulation of neurotoxic intermediates and compromises production of neuronal support factors, contributing to axonal degeneration, endothelial dysfunction and diabetic neuropathy. Abstract | The prevalence of diabetes worldwide is at pandemic levels, with the number of patients increasing by 5% annu...

show abstract

Section: Schwann Cells In Diabetic Neuropathymentioning

confidence: 99%

Schwann cell interactions with axons and microvessels in diabetic neuropathy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…There are several risk factors associated to the development and progression of DSP, among them advanced age, male gender, non-hispanic blacks, longer DM duration, glycosilated hemoglobin (HbA1c) higher than 7%, insulin therapy and history of systemic hypertension (SH), DLP and albuminuria 51 .…”

Section: Risk Factorsmentioning

confidence: 99%

Diabetic neuropathy

Nascimento¹,

Pupe²,

Cavalcanti³

2016

Revista Dor

View full text Add to dashboard Cite

“…Hallazgos similares se han encontrado en otros estudios inclusive con frecuencias menores (10,11); sin embargo, también existen estudios que describen frecuencias elevadas hasta de 75% con buenos valores de sensibilidad, especificidad y valores predictivos (12)(13)(14). El amplio de las frecuencias halladas con el uso del MNSI puede deberse a que la frecuencia de los factores de riesgo para NDP como edad, valores de hemoglobina glicosilada, tiempo de enfermedad, fue muy distinta entre estos estudios y solo algunos compararon el MNSI con la VCN (9,12,15).…”

Section: Discussionunclassified